AU2003246774B2 - Novel association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases - Google Patents

Novel association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases Download PDF

Info

Publication number
AU2003246774B2
AU2003246774B2 AU2003246774A AU2003246774A AU2003246774B2 AU 2003246774 B2 AU2003246774 B2 AU 2003246774B2 AU 2003246774 A AU2003246774 A AU 2003246774A AU 2003246774 A AU2003246774 A AU 2003246774A AU 2003246774 B2 AU2003246774 B2 AU 2003246774B2
Authority
AU
Australia
Prior art keywords
compound
aspirin
pharmaceutical composition
pharmaceutically acceptable
synergistic combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003246774A
Other languages
English (en)
Other versions
AU2003246774A1 (en
Inventor
Bernard Cimetiere
Gilbert Lavielle
Marie-Odile Vallez
Tony Verbeuren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of AU2003246774A1 publication Critical patent/AU2003246774A1/en
Application granted granted Critical
Publication of AU2003246774B2 publication Critical patent/AU2003246774B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2003246774A 2002-04-05 2003-04-04 Novel association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases Ceased AU2003246774B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0204222A FR2838057B1 (fr) 2002-04-05 2002-04-05 Nouvelle association d'un antithrombotique et d'aspirine
FR02/04222 2002-04-05
PCT/FR2003/001054 WO2003084525A1 (fr) 2002-04-05 2003-04-04 Nouvelle association d'un antithrombotique et d'aspirine

Publications (2)

Publication Number Publication Date
AU2003246774A1 AU2003246774A1 (en) 2003-10-20
AU2003246774B2 true AU2003246774B2 (en) 2007-02-15

Family

ID=28052120

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003246774A Ceased AU2003246774B2 (en) 2002-04-05 2003-04-04 Novel association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases

Country Status (26)

Country Link
US (1) US7618955B2 (cg-RX-API-DMAC7.html)
EP (1) EP1496884B1 (cg-RX-API-DMAC7.html)
JP (1) JP4065853B2 (cg-RX-API-DMAC7.html)
KR (1) KR100645143B1 (cg-RX-API-DMAC7.html)
CN (1) CN1297265C (cg-RX-API-DMAC7.html)
AR (1) AR039253A1 (cg-RX-API-DMAC7.html)
AT (1) ATE329591T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003246774B2 (cg-RX-API-DMAC7.html)
BR (1) BR0309019A (cg-RX-API-DMAC7.html)
CA (1) CA2480697A1 (cg-RX-API-DMAC7.html)
CY (1) CY1105106T1 (cg-RX-API-DMAC7.html)
DE (1) DE60306133T2 (cg-RX-API-DMAC7.html)
DK (1) DK1496884T3 (cg-RX-API-DMAC7.html)
EA (1) EA006978B1 (cg-RX-API-DMAC7.html)
ES (1) ES2264533T3 (cg-RX-API-DMAC7.html)
FR (1) FR2838057B1 (cg-RX-API-DMAC7.html)
GE (1) GEP20074101B (cg-RX-API-DMAC7.html)
MA (1) MA27114A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04009760A (cg-RX-API-DMAC7.html)
NO (1) NO20044700L (cg-RX-API-DMAC7.html)
NZ (1) NZ535430A (cg-RX-API-DMAC7.html)
PL (1) PL371620A1 (cg-RX-API-DMAC7.html)
PT (1) PT1496884E (cg-RX-API-DMAC7.html)
UA (1) UA79457C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003084525A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200407593B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2376994C2 (ru) * 2005-07-22 2009-12-27 Дзе Проктер Энд Гэмбл Компани Составы для снижения риска возникновения вызванной лекарственными средствами аритмии
EP2155195B1 (en) 2007-04-13 2014-07-16 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
JP2009001537A (ja) * 2007-06-25 2009-01-08 Lab Servier 血管障害の処置を目的とする医薬の入手における抗アテローム血栓化合物の使用
FR2920772B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711139B1 (fr) * 1993-10-15 1995-12-01 Adir Nouveaux dérivés de 1,2,3,4-tétrahydronaphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
NO20044700L (no) 2004-10-29
MA27114A1 (fr) 2004-12-20
NZ535430A (en) 2006-09-29
CN1297265C (zh) 2007-01-31
US7618955B2 (en) 2009-11-17
GEP20074101B (en) 2007-05-10
DE60306133D1 (de) 2006-07-27
KR100645143B1 (ko) 2006-11-10
AR039253A1 (es) 2005-02-16
WO2003084525A1 (fr) 2003-10-16
FR2838057A1 (fr) 2003-10-10
CN1646111A (zh) 2005-07-27
HK1076034A1 (en) 2006-01-06
AU2003246774A1 (en) 2003-10-20
EP1496884A1 (fr) 2005-01-19
ES2264533T3 (es) 2007-01-01
KR20040098053A (ko) 2004-11-18
CY1105106T1 (el) 2009-11-04
EA200401293A1 (ru) 2005-02-24
EA006978B1 (ru) 2006-06-30
JP2005528376A (ja) 2005-09-22
CA2480697A1 (fr) 2003-10-16
US20050143354A1 (en) 2005-06-30
ZA200407593B (en) 2006-07-26
UA79457C2 (en) 2007-06-25
MXPA04009760A (es) 2004-12-13
EP1496884B1 (fr) 2006-06-14
DE60306133T2 (de) 2007-01-04
FR2838057B1 (fr) 2005-07-08
ATE329591T1 (de) 2006-07-15
PL371620A1 (en) 2005-06-27
DK1496884T3 (da) 2006-10-02
JP4065853B2 (ja) 2008-03-26
BR0309019A (pt) 2005-02-01
PT1496884E (pt) 2006-09-29

Similar Documents

Publication Publication Date Title
JP2632754B2 (ja) 脳内グルタミン酸遊離抑制剤
US7618955B2 (en) Association of an antithrombotic and aspirin
Sabbatini et al. Nicardipine and treatment of cerebrovascular diseases with particular reference to hypertension-related disorders
US20100056564A1 (en) Association of an anti-atherothrombotic agent and an anti-platelet-aggregation agent
AU639722B2 (en) Use of arylalkylamides in the treatment of neurodegenerative diseases
JP2005528376A5 (cg-RX-API-DMAC7.html)
HK1076034B (en) Novel association of an antithrombotic agent with aspirin and use thereof for the manufacture of a medicament for treating atherothrombotic diseases
HK1093900B (en) Novel association consisting of an anti-atherothrombotic agent and of a platelet antiaggregating agent
HK40029182A (en) Sublingual formulation with water-soluble cocrystals of acetylsalicylic acid with citric acid, sodium bicarbonate, and l-theanine for the treatment of acute myocardial infarction
EP0115331A1 (en) Medicament for cerebral apoplexy
WO2004075893A1 (en) Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker
JPWO2017217072A1 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤
JPWO1998035673A1 (ja) 末梢循環障害改善剤
JP2007508242A (ja) トロンボキサンa2受容体アンタゴニストとシクロオキシゲネーゼ−1の阻害剤との組み合わせを伴う組成物および方法
JP2001048806A (ja) 薬害障害の軽減された抗炎症剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired